Due to its unclear etiology, there is no specific medicine to cure the recurrent and incurable inflammatory bowel disease (IBD). Unhealthy dietary habits unconsciously contributed to the progression of IBD, for example a High-Salt-Diet (HSD) is the most neglected and frequently adopted habit. However, the molecular mechanism of how HSD aggravates the progression of IBD has yet to remain uncovered. Herein, we focus on the hypothesis that necroptosis pathway may be involved in the process of IBD exacerbated by HSD. To this end, different gene expression (DEGs) profiles of human epithelia under hypertonic culture conditions were applied to screen candidate pathways. What's more, gene expression manipulation, immune microenvironment detection, RIPK3/MLKL gene knockout (KO), and wild-type (WT) mice were carried out to research the promotion of IBD progression under treatments of high salt intake. Based on our present results, gene expression profiles in human normal colon epithelia cell NCM460 were significantly changed under salt- or sucrose-induced hypertonic culture conditions. RIPK3 was significantly up-regulated under both conditions. Furthermore, mice colon epithelia cell CT26 growth was inhibited in a time- and dose-dependent manner by extra NaCl incubation. Autophagy, and Necroptosis pathways were activated and enhanced by LPS pretreatment. HSD significantly exacerbated DSS-induced IBD symptoms in vivo in a dose-dependent manner. Moreover, RIPK3-/- and MLKL-/- mice presented severe IBD symptoms in vivo. Overall, the results demonstrated that HSD aggravated the IBD progression via necroptosis activation, providing novel strategies and promising targets for the clinical treatment of IBD. Highlights 1. High-salt and high-sucrose incubation enhanced RIPK3-dependent necroptosis in colonic epithelial cell. 2. HSD promotes DSS-induced IBD progression in a dose-dependent manner. 3. RIPK3 and MLKL genetic deletion significantly susceptible to IBD process.
基金:
Yunnan Digestive Endoscopy Clinical Medical Center Foundation for Health Commission of Yunnan Province [2021LCZXXF-XH018, 2022LCZXKF-XH01, 2X2019-01-02]; Yunnan Provincial Key Laboratory of Clinical Virology [202205AG070053]; First People's Hospital of Yunnan Province PHD program [KHBS-2022013]; Kunming Medical University Joint Special Project on Applied Basic Research [202301AY070001-007]; Yunnan Province Famous Doctor program [KH-SWR-MY-2019-009]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|4 区医学
小类|4 区生化与分子生物学4 区细胞生物学4 区医学:研究与实验
最新[2023]版:
大类|4 区医学
小类|4 区生化与分子生物学4 区细胞生物学4 区医学:研究与实验
JCR分区:
出版当年[2022]版:
无
最新[2023]版:
Q1CELL BIOLOGYQ1MEDICINE, RESEARCH & EXPERIMENTALQ1BIOCHEMISTRY & MOLECULAR BIOLOGY